{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T17:06:33Z","timestamp":1790960793941,"version":"4.1.0"},"reference-count":228,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T00:00:00Z","timestamp":1695340800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Reports"],"abstract":"<jats:p>During the COVID-19 pandemic, it became apparent that precision medicine relies heavily on biological multi-omics discoveries. High throughput omics technologies, such as host genomics, transcriptomics, proteomics, epigenomics, metabolomics\/lipidomics, and microbiomics, have become an integral part of precision diagnostics. The large number of data generated by omics technologies allows for the identification of vulnerable demographic populations that are susceptible to poor disease outcomes. Additionally, these data help to pinpoint the omics-based biomarkers that are currently driving advancements in precision and preventive medicine, such as early diagnosis and disease prognosis, individualized treatments, and vaccination. This report summarizes COVID-19-omic studies, highlights the results of completed and ongoing omics investigations in individuals who have experienced severe disease outcomes, and examines the impact that repurposed\/novel antiviral drugs, targeted immunotherapeutics, and vaccines have had on individual and public health.<\/jats:p>","DOI":"10.3390\/reports6040045","type":"journal-article","created":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T03:44:42Z","timestamp":1695354282000},"page":"45","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["COVID-19-Omics Report: From Individual Omics Approaches to Precision Medicine"],"prefix":"10.3390","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0795-4723","authenticated-orcid":false,"given":"Irina","family":"Vlasova-St. Louis","sequence":"first","affiliation":[{"name":"Individualized Genomics and Health Program, Johns Hopkins University, Baltimore, MD 21218, USA"},{"name":"APHL-CDC Laboratory Program, Silver Spring, MD 20910, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel","family":"Fang","sequence":"additional","affiliation":[{"name":"APHL-CDC Laboratory Program, Silver Spring, MD 20910, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yara","family":"Amer","sequence":"additional","affiliation":[{"name":"Department of Medicine, Al Ahrar Teaching Hospital, Zagazig 44511, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1384-5128","authenticated-orcid":false,"given":"Hesham","family":"Mohei","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,9,22]]},"reference":[{"key":"ref_1","unstructured":"Louis, I.V., Gorzalski, A., and Pandori, M. (2021). Applications of RNA-Seq in Biology and Medicine, IntechOpen."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jmoldx.2023.01.005","article-title":"Rapid Lineage Assignment of Severe Acute Respiratory Syndrome Coronavirus 2 Cases through Automated Library Preparation, Sequencing, and Bioinformatic Analysis","volume":"25","author":"Gorzalski","year":"2023","journal-title":"J. Mol. Diagn."},{"key":"ref_3","first-page":"155","article-title":"Coronavirus biology and replication: Implications for SARS-CoV-2","volume":"19","author":"Kratzel","year":"2020","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Wang, M.Y., Zhao, R., Gao, L.J., Gao, X.F., Wang, D.P., and Cao, J.M. (2020). SARS-CoV-2: Structure, Biology, and Structure-Based Therapeutics Development. Front. Cell. Infect. Microbiol., 10.","DOI":"10.3389\/fcimb.2020.587269"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.bsheal.2023.01.002","article-title":"Towards precision medicine: Omics approach for COVID-19","volume":"5","author":"Cen","year":"2023","journal-title":"Biosaf. Health"},{"key":"ref_6","unstructured":"Statista (2023, May 26). Distribution of Total COVID-19 Deaths in the United States as of 26 April 2023, by Age Group. Available online: https:\/\/www.statista.com\/statistics\/1254488\/us-share-of-total-covid-deaths-by-age-group\/."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"7717","DOI":"10.1038\/s41598-023-34678-8","article-title":"Impaired health-related quality of life in long-COVID syndrome after mild to moderate COVID-19","volume":"13","author":"Malesevic","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1038\/s41579-022-00846-2","article-title":"Long COVID: Major findings, mechanisms and recommendations","volume":"21","author":"Davis","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Y\u00fcce, M., Filiztekin, E., and \u00d6zkaya, K.G. (2021). COVID-19 Diagnosis\u2014A review of current methods. Biosens. Bioelectron., 172.","DOI":"10.1016\/j.bios.2020.112752"},{"key":"ref_10","unstructured":"Louis, I.V. (2023). RNA Therapeutics\u2014History, Design, Manufacturing, and Applications, IntechOpen."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"362","DOI":"10.7326\/M20-3012","article-title":"Prevalence of asymptomatic SARS-CoV-2 infection. A narrative review","volume":"173","author":"Oran","year":"2020","journal-title":"Ann. Intern. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.2147\/IJGM.S316708","article-title":"The conundrum of \u2018long-covid-19\u02b9: A narrative review","volume":"14","author":"Garg","year":"2021","journal-title":"Int. J. Gen. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e2137257","DOI":"10.1001\/jamanetworkopen.2021.37257","article-title":"Global Percentage of Asymptomatic SARS-CoV-2 Infections among the Tested Population and Individuals with Confirmed COVID-19 Diagnosis: A Systematic Review and Meta-analysis","volume":"4","author":"Ma","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"285","DOI":"10.7326\/L20-1279","article-title":"Prevalence of Asymptomatic SARS-CoV-2 Infection","volume":"174","author":"Elder","year":"2021","journal-title":"Ann. Intern. Med."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19","volume":"181","author":"Liu","year":"2020","journal-title":"Cell"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S2213-2600(21)00075-8","article-title":"SARS-CoV-2 evolution and vaccines: Cause for concern?","volume":"9","author":"Williams","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_17","first-page":"354","article-title":"Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Reinfection by a Phylogenetically Distinct Strain","volume":"73","author":"Vermeersch","year":"2020","journal-title":"Clin. Infect. Dis."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"583777","DOI":"10.3389\/fphar.2020.583777","article-title":"Calming the Storm: Natural Immunosuppressants as Adjuvants to Target the Cytokine Storm in COVID-19","volume":"11","author":"Peter","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1038\/s41392-021-00679-0","article-title":"The signal pathways and treatment of cytokine storm in COVID-19","volume":"6","author":"Yang","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_20","unstructured":"India TRC (2023, June 06). BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots. NCT04475302, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04475302."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"20","DOI":"10.21315\/mjms2021.28.6.3","article-title":"The effect of influenza vaccination on covid-19 morbidity, severity and mortality: Systematic review and meta-analysis","volume":"28","author":"Behnampour","year":"2021","journal-title":"Malays. J. Med. Sci."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1016\/j.jaci.2016.05.035","article-title":"Rapid molecular diagnostics of severe primary immunodeficiency determined by using targeted next-generation sequencing","volume":"138","author":"Yu","year":"2016","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.3389\/fimmu.2020.01417","article-title":"Second-Tier Next Generation Sequencing Integrated in Nationwide Newborn Screening Provides Rapid Molecular Diagnostics of Severe Combined Immunodeficiency","volume":"11","author":"Strand","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_24","unstructured":"IDF (Immunodeficiency Foundation) (2021, May 07). Severe Combined Immunodeficiency and Combined Immunodeficiency. Available online: https:\/\/primaryimmune.org\/scid-compass\/disease\/severe-combined-immunodeficiency-and-combined-immunodeficiency."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"e10","DOI":"10.1093\/pch\/21.2.e10","article-title":"Primary immunodeficiency for the primary care provider","volume":"21","author":"Halbrich","year":"2016","journal-title":"Paediatr. Child. Health"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"S72","DOI":"10.1542\/peds.2021-053843BBBBB","article-title":"Inborn Errors of Type I IFN Immunity in Patients With Life-Threatening COVID-19","volume":"148","author":"Orange","year":"2021","journal-title":"Pediatrics"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"373","DOI":"10.3389\/fped.2019.00373","article-title":"Universal Newborn Screening for Severe Combined Immunodeficiency (SCID)","volume":"7","author":"Mahlaoui","year":"2019","journal-title":"Front. Pediatr."},{"key":"ref_28","unstructured":"CDC (2021, May 06). Newborn Screening Portal, Available online: https:\/\/www.cdc.gov\/newbornscreening\/index.html."},{"key":"ref_29","unstructured":"ClinicalTrials (2023, June 02). Analysis of the Immune Response to COVID-19 Vaccination and Outcomes in Individuals With and Without Immune Deficiencies and Dysregulations. NCT04852276, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04852276."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1007\/s40121-021-00447-1","article-title":"Prevalence and Mortality due to COVID-19 in HIV Co-Infected Population: A Systematic Review and Meta-Analysis","volume":"10","author":"Liang","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Baek, M.S., Lee, M.T., Kim, W.Y., Choi, J.C., and Jung, S.Y. (2021). COVID-19-related outcomes in immunocompromised patients: A nationwide study in Korea. PLoS ONE, 16.","DOI":"10.1371\/journal.pone.0257641"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Tamuzi, J.L., Ayele, B.T., Shumba, C.S., Adetokunboh, O.O., Uwimana-Nicol, J., Haile, Z.T., Inugu, J., and Nyasulu, P.S. (2020). Implications of COVID-19 in high burden countries for HIV\/TB: A systematic review of evidence. BMC Infect. Dis., 20.","DOI":"10.1186\/s12879-020-05450-4"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s13045-021-01046-w","article-title":"COVID-19 vaccines for patients with cancer: Benefits likely outweigh risks","volume":"14","author":"Hwang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1093\/ajhp\/zxab344","article-title":"COVID-19 vaccine use in immunocompromised patients: A commentary on evidence and recommendations","volume":"79","author":"Duly","year":"2022","journal-title":"Am. J. Health Pharm."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"e20596","DOI":"10.2196\/20596","article-title":"Mobile Health Apps That Help With COVID-19 Management: Scoping Review","volume":"3","author":"Couch","year":"2020","journal-title":"JMIR Nurs."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1001\/jamapediatrics.2021.0038","article-title":"Assessment of Maternal and Neonatal Cord Blood SARS-CoV-2 Antibodies and Placental Transfer Ratios","volume":"175","author":"Flannery","year":"2021","journal-title":"JAMA Pediatr."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e2030455","DOI":"10.1001\/jamanetworkopen.2020.30455","article-title":"Assessment of Maternal and Neonatal SARS-CoV-2 Viral Load, Transplacental Antibody Transfer, and Placental Pathology in Pregnancies During the COVID-19 Pandemic","volume":"3","author":"Edlow","year":"2020","journal-title":"JAMA Netw. Open"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e100","DOI":"10.1056\/NEJMc2009226","article-title":"Clinical Characteristics of Pregnant Women with Covid-19 in Wuhan, China","volume":"382","author":"Chen","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/j.ejogrb.2020.07.008","article-title":"Maternal COVID-19 infection, clinical characteristics, pregnancy, and neonatal outcome: A prospective cohort study","volume":"252","author":"Antoun","year":"2020","journal-title":"Eur. J. Obstet. Gynecol. Reprod. Biol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"E540","DOI":"10.1503\/cmaj.202604","article-title":"The impact of COVID-19 on pregnancy outcomes: A systematic review and meta-analysis","volume":"193","author":"Wei","year":"2021","journal-title":"CMAJ"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e2314350","DOI":"10.1001\/jamanetworkopen.2023.14350","article-title":"COVID-19 Booster Vaccination in Early Pregnancy and Surveillance for Spontaneous Abortion","volume":"6","author":"Kharbanda","year":"2023","journal-title":"JAMA Netw. Open"},{"key":"ref_42","unstructured":"CDC (2023, May 25). Centers for Disease Control and Prevention Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States, Available online: https:\/\/www.cdc.gov\/vaccines\/covid-19\/clinical-considerations\/covid-19-vaccines-us.html#pregnant."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1056\/NEJMoa2021680","article-title":"Multisystem Inflammatory Syndrome in U.S. Children and Adolescents","volume":"383","author":"Feldstein","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Grier, J.T., Cron, R.Q., Dos, S., Faccion, R.S., Amendola, F., Carvalho, A.D., Campelo, D., Cox, B., Celia, M., and Zuma, C. (2023). Rare genetic variants involved in multisystem inflammatory syndrome in children: A multicenter Brazilian cohort study. Front. Cell. Infect. Microbiol., 13.","DOI":"10.3389\/fcimb.2023.1182257"},{"key":"ref_45","unstructured":"(2023, June 04). NCT04644146. Genetic Predisposition to Severe Forms of COVID-19 (SARS-CoV2 Infection) (COVIDGEN), Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04644146."},{"key":"ref_46","unstructured":"(2023, June 05). NCT04384250. Genetic and Immunologic Basis of COVID-19 Infection, Available online: https:\/\/classic.clinicaltrials.gov\/ct2\/show\/NCT04384250."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/s41576-022-00478-5","article-title":"The human genetic epidemiology of COVID-19","volume":"23","author":"Niemi","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"COVID-19 Host Genetics Initiative (2022). A first update on mapping the human genetic architecture of COVID-19. Nature, 608, E1\u2013E10.","DOI":"10.1038\/s41586-022-04826-7"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1073\/pnas.2116435119","article-title":"The major genetic risk factor for severe COVID-19 is associated with protection against HIV","volume":"119","author":"Zeberg","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5761","DOI":"10.1038\/s41467-020-19623-x","article-title":"Associations between blood type and COVID-19 infection, intubation, and death","volume":"11","author":"Zietz","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1111\/tan.14284","article-title":"The influence of HLA genotype on the severity of COVID-19 infection","volume":"98","author":"Langton","year":"2021","journal-title":"HLA"},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Vig\u00f3, L.I., Gal\u00e1, M.I., Torres, M., Mart\u00edn-Galiano, A.J., Rodr\u00edguez-Mora, S., Mateos, E., Corona, M., Malo, R., Navarro, C., and Ar\u00e1 nzazu Murciano-Ant\u00f3, M. (2022). Association between HLA-C alleles and COVID-19 severity in a pilot study with a Spanish Mediterranean Caucasian cohort. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0272867"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Nguyen, A., David, J.K., Maden, S.K., Wood, M.A., Weeder, B.R., Nellore, A., and Thompson, R.F. (2020). Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2. J. Virol., 94.","DOI":"10.1128\/JVI.00510-20"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Dieter, C., de Almeida Brondani, L., Bauermann Leit\u00e3o, C., Gerchman, F., lia Emerim Lemos, N., and Crispim, D.I. (2022). Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: A systematic review and meta-analysis. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0270627"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"e2323","DOI":"10.1002\/rmv.2323","article-title":"Genetic polymorphisms of ACE1, ACE2, and TMPRSS2 associated with COVID-19 severity: A systematic review with meta-analysis","volume":"32","author":"Saengsiwaritt","year":"2022","journal-title":"Rev. Med. Virol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/s41421-021-00318-6","article-title":"Genome-wide association study of COVID-19 severity among the Chinese population","volume":"7","author":"Li","year":"2021","journal-title":"Cell Discov."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1093\/ajcp\/aqac036","article-title":"ABO Blood Groups Are Not Associated With COVID-19 Disease Incidence and Severity When Correcting for Ethnicity Differences in Blood Type","volume":"158","author":"Pasko","year":"2022","journal-title":"Am. J. Clin. Pathol."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"859387","DOI":"10.3389\/fimmu.2022.859387","article-title":"The Genetic Risk for COVID-19 Severity Is Associated With Defective Immune Responses","volume":"13","author":"Kuijpers","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Elek, Z., Losoncz, E., Maricza, K., F\u00fclep, Z., B\u00e1nlaki, Z., Kov\u00e1cs-Nagy, R., Keszler, G., and R\u00f3nai, Z. (2023). Missense Variants of von Willebrand Factor in the Background of COVID-19 Associated Coagulopathy. Genes, 14.","DOI":"10.3390\/genes14030617"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1016\/j.ekir.2022.09.027","article-title":"Renal Prognosis of COVID-19 Associated Nephropathy","volume":"7","author":"Giannini","year":"2022","journal-title":"Kidney Int. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"105426","DOI":"10.1016\/j.meegid.2023.105426","article-title":"Genetic susceptibility to severe COVID-19","volume":"110","author":"Cappadona","year":"2023","journal-title":"Infect. Genet. Evol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"146674","DOI":"10.1016\/j.gene.2022.146674","article-title":"The association of COVID-19 severity and susceptibility and genetic risk factors: A systematic review of the literature","volume":"836","author":"Ishak","year":"2022","journal-title":"Gene"},{"key":"ref_63","doi-asserted-by":"crossref","unstructured":"Pecoraro, V., Cuccorese, M., and Trenti, T. (Clin. Exp. Med., 2023). Genetic polymorphisms of ACE1, ACE2, IFTM3, TMPRSS2 and TNF\u03b1 genes associated with susceptibility and severity of SARS-CoV-2 infection: A systematic review and meta-analysis, Clin. Exp. Med., online ahead of print.","DOI":"10.1007\/s10238-023-01038-9"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1111\/tan.14560","article-title":"Association of HLA gene polymorphism with susceptibility, severity, and mortality of COVID-19: A systematic review","volume":"99","author":"Deb","year":"2022","journal-title":"HLA"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13073-022-01100-3","article-title":"Clinical implications of host genetic variation and susceptibility to severe or critical COVID-19","volume":"14","author":"Netea","year":"2022","journal-title":"Genome Med."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Severe COVID-19 GWAS Group (2020). Genomewide association study of severe COVID-19 with respiratory failure. N. Engl. J. Med., 383, 1522\u20131534.","DOI":"10.1056\/NEJMe2025501"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00251-022-01261-w","article-title":"COVID-19: Impact on Public Health and hypothesis-driven investigations on genetic susceptibility and severity","volume":"74","author":"David","year":"2022","journal-title":"Immunogenetics"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13148-020-00946-x","article-title":"The epigenetic implication in coronavirus infection and therapy","volume":"12","author":"Atlante","year":"2020","journal-title":"Clin. Epigenetics"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"581726","DOI":"10.3389\/fgene.2021.581726","article-title":"Epigenetic Lens to Visualize the Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Infection in COVID-19 Pandemic","volume":"12","author":"Saksena","year":"2021","journal-title":"Front. Genet."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1016\/j.bja.2020.06.060","article-title":"Epigenetic susceptibility to severe respiratory viral infections and its therapeutic implications: A narrative review","volume":"125","author":"Crimi","year":"2020","journal-title":"Br. J. Anaesth."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.clim.2020.108410","article-title":"Epigenetic dysregulation of ACE2 and interferon-regulated genes might suggest increased COVID-19 susceptibility and severity in lupus patients","volume":"215","author":"Sawalha","year":"2020","journal-title":"Clin. Immunol."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Sang, E.R., Tian, Y., Miller, L.C., and Sang, Y. (2021). Epigenetic evolution of ACE2 and IL-6 genes: Non-canonical interferon-stimulated genes correlate to COVID-19 susceptibility in vertebrates. Genes, 12.","DOI":"10.1101\/2020.09.09.273268"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1007\/s40995-022-01334-1","article-title":"Influence of Disease Severity and Gender on HLA-C Methylation in COVID-19 Patients","volume":"46","author":"Asadikaram","year":"2022","journal-title":"Iran. J. Sci. Technol. Trans. A Sci."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Khan, M.A.A.K., and Islam, A.B.M.M.K. (2021). SARS-CoV-2 Proteins Exploit Host\u2019s Genetic and Epigenetic Mediators for the Annexation of Key Host Signaling Pathways. Front. Mol. Biosci., 7.","DOI":"10.3389\/fmolb.2020.598583"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1048790","DOI":"10.3389\/fimmu.2023.1048790","article-title":"Vitamin B12 attenuates leukocyte inflammatory signature in COVID-19 via methyl-dependent changes in epigenetic markings","volume":"14","author":"Cassiano","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_76","unstructured":"Ali Ahmed Eid, M. (2023, May 17). Differential Expression of Cytokines, Transcriptome and miRNA in Coronavirus Disease 2019 (COVID-19) Egyptian\u2019s Patients, Available online: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04583566."},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Salgado-Albarr\u00e1n, M., Navarro-Delgado, E.I., Del Moral-Morales, A., Alcaraz, N., Baumbach, J., Gonz\u00e1lez-Barrios, R., and Soto-Reyes, E. (2021). Comparative transcriptome analysis reveals key epigenetic targets in SARS-CoV-2 infection. NPJ Syst. Biol. Appl., 7.","DOI":"10.1038\/s41540-021-00181-x"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1007\/s11306-021-01859-3","article-title":"Untargeted metabolomics of COVID-19 patient serum reveals potential prognostic markers of both severity and outcome","volume":"18","author":"Roberts","year":"2022","journal-title":"Metabolomics"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"e140327","DOI":"10.1172\/jci.insight.140327","article-title":"COVID-19 infection alters kynurenine and fatty acid metabolism, correlating with IL-6 levels and renal status","volume":"5","author":"Thomas","year":"2020","journal-title":"JCI Insight"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1038\/s41419-021-03540-y","article-title":"Metabolomic analyses of COVID-19 patients unravel stage-dependent and prognostic biomarkers","volume":"12","author":"Danlos","year":"2021","journal-title":"Cell Death Dis."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Meoni, G., Ghini, V., Maggi, L., Vignoli, A., Mazzoni, A., Salvati, L., Capone, M., Vanni, A., Tenori, L., and Fontanari, P. (2021). Metabolomic\/lipidomic profiling of COVID-19 and individual response to tocilizumab. PLoS Pathog., 17.","DOI":"10.1371\/journal.ppat.1009243"},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Ghini, V., Meoni, G., Pelagatti, L., Celli, T., Veneziani, F., Petrucci, F., Vannucchi, V., Bertini, L., Luchinat, C., and Landini, G. (2022). Profiling metabolites and lipoproteins in COMETA, an Italian cohort of COVID-19 patients. PLoS Pathog., 18.","DOI":"10.1371\/journal.ppat.1010443"},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Barberis, E., Timo, S., Amede, E., Vanella, V.V., Puricelli, C., Cappellano, G., Raineri, D., Cittone, M.G., Rizzi, E., and Pedrinelli, A.R. (2020). Large-scale plasma analysis revealed new mechanisms and molecules associated with the host response to sars-cov-2. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21228623"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"4618","DOI":"10.7150\/ijbs.72450","article-title":"Effect of a Functional Phospholipid Metabolome-Protein Association Pathway on the Mechanism of COVID-19 Disease Progression","volume":"18","author":"Xue","year":"2022","journal-title":"Int. J. Biol. Sci."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1186\/s12967-020-02488-5","article-title":"The importance of Vitamin D metabolism as a potential prophylactic, immunoregulatory and neuroprotective treatment for COVID-19","volume":"18","author":"Xu","year":"2020","journal-title":"J. Transl. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"e40","DOI":"10.1017\/jns.2020.36","article-title":"COVID-19: The older adult and the importance of vitamin D sufficiency","volume":"9","author":"Griffin","year":"2020","journal-title":"J. Nutr. Sci."},{"key":"ref_87","doi-asserted-by":"crossref","unstructured":"Infusino, F., Marazzato, M., Mancone, M., Fedele, F., Mastroianni, C.M., Severino, P., Ceccarelli, G., Santinelli, L., Cavarretta, E., and Marullo, A.G.M. (2020). Diet supplementation, probiotics, and nutraceuticals in SARS-CoV-2 infection: A scoping review. Nutrients, 12.","DOI":"10.3390\/nu12061718"},{"key":"ref_88","doi-asserted-by":"crossref","unstructured":"Chattopadhyay, I., and Shankar, E.M. (2021). SARS-CoV-2-Indigenous Microbiota Nexus: Does Gut Microbiota Contribute to Inflammation and Disease Severity in COVID-19?. Front. Cell. Infect. Microbiol., 11.","DOI":"10.3389\/fcimb.2021.590874"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1053\/j.gastro.2020.03.045","article-title":"Multiomics Evaluation of Gastrointestinal and Other Clinical Characteristics of COVID-19","volume":"158","author":"Du","year":"2020","journal-title":"Gastroenterology"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Merenstein, C., Liang, G., Whiteside, S.A., Cobi\u00e1n-G\u00fcemes, A.G., Merlino, M.S., Taylor, L.J., Glascock, A., Bittinger, K., Tanes, C., and Graham-Wooten, J. (2021). Signatures of COVID-19 Severity and Immune Response in the Respiratory Tract Microbiome. MBio, 12.","DOI":"10.1128\/mBio.01777-21"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Gohil, K., Samson, R., Dastager, S., and Dharne, M. (2021). Probiotics in the prophylaxis of COVID-19: Something is better than nothing. 3 Biotech, 11.","DOI":"10.1007\/s13205-020-02554-1"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s12291-020-00948-9","article-title":"COVID-19 and Gut Microbiota: A Potential Connection","volume":"36","author":"Rajput","year":"2021","journal-title":"Indian. J. Clin. Biochem."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1186\/s12934-020-01483-1","article-title":"Dual and mutual interaction between microbiota and viral infections: A possible treat for COVID-19","volume":"19","author":"Baghbani","year":"2020","journal-title":"Microb. Cell Fact."},{"key":"ref_94","doi-asserted-by":"crossref","unstructured":"He, Y., Wang, J., Li, F., and Shi, Y. (2020). Main Clinical Features of COVID-19 and Potential Prognostic and Therapeutic Value of the Microbiota in SARS-CoV-2 Infections. Front. Microbiol., 11.","DOI":"10.3389\/fmicb.2020.01302"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Hirota, M., Tamai, M., Yukawa, S., Taira, N., Matthews, M.M., Toma, T., Seto, Y., Yoshida, M., Toguchi, S., and Miyagi, M. (2023). Human immune and gut microbial parameters associated with inter-individual variations in COVID-19 mRNA vaccine-induced immunity. Commun. Biol., 6.","DOI":"10.1038\/s42003-023-04755-9"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"30404","DOI":"10.1016\/S2213-2600(20)30404-5","article-title":"Cytokine elevation in severe and critical COVID-19: A rapid systematic review, meta-analysis, and comparison with other inflammatory syndromes","volume":"8","author":"Leisman","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1097\/MCC.0000000000000786","article-title":"Biomarkers in acute respiratory distress syndrome","volume":"27","author":"Jabaudon","year":"2021","journal-title":"Curr. Opin. Crit. Care"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13073-020-00823-5","article-title":"Disease severity-specific neutrophil signatures in blood transcriptomes stratify COVID-19 patients","volume":"13","author":"Aschenbrenner","year":"2020","journal-title":"Genome Med."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"eabd7114","DOI":"10.1126\/sciimmunol.abd7114","article-title":"Comprehensive mapping of immune perturbations associated with severe COVID-19","volume":"5","author":"Pampena","year":"2020","journal-title":"Sci. Immunol."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/j.cell.2021.01.053","article-title":"COVID-19 immune features revealed by a large-scale single-cell transcriptome atlas","volume":"184","author":"Ren","year":"2021","journal-title":"Cell"},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Neufeldt, C.J., Cerikan, B., Cortese, M., Frankish, J., Lee, J.Y., Plociennikowska, A., Heigwer, F., Prasad, V., Joecks, S., and Burkart, S.S. (2022). SARS-CoV-2 infection induces a pro-inflammatory cytokine response through cGAS-STING and NF-\u03baB. Commun. Biol., 5.","DOI":"10.1038\/s42003-021-02983-5"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1016\/j.cell.2021.02.029","article-title":"COVID-19 and the human innate immune system","volume":"184","author":"Schultze","year":"2021","journal-title":"Cell"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"e24321","DOI":"10.1097\/MD.0000000000024321","article-title":"Novel signaling pathways regulate SARS-CoV and SARS-CoV-2 infectious disease","volume":"100","author":"Cheng","year":"2021","journal-title":"Medicine"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Mahmood, H.Z., Madhavarapu, S., and Almuqamam, M. (2021). Varying Illness Severity in Patients with MyD88 Deficiency Infected with Coronavirus SARS-CoV-2, American Academy of Pediatrics (AAP).","DOI":"10.1542\/peds.147.3_MeetingAbstract.453"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3389\/fimmu.2020.01021","article-title":"Novel Coronavirus-Induced NLRP3 Inflammasome Activation: A Potential Drug Target in the Treatment of COVID-19","volume":"11","author":"Shah","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"799558","DOI":"10.3389\/fimmu.2021.799558","article-title":"Persistent Oxidative Stress and Inflammasome Activation in CD14highCD16\u2212 Monocytes From COVID-19 Patients","volume":"12","author":"Lage","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"16814","DOI":"10.1038\/s41598-021-96110-3","article-title":"SARS-CoV-2 infection initiates interleukin-17-enriched transcriptional response in different cells from multiple organs","volume":"11","author":"Hasan","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s10787-020-00773-9","article-title":"The Role and Therapeutic Potential of NF-kappa-B Pathway in Severe COVID-19 Patients","volume":"29","author":"Hariharan","year":"2021","journal-title":"Inflammopharmacology"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"155719","DOI":"10.1016\/j.cyto.2021.155719","article-title":"Randomized trial drug controlled compendious transcriptome analysis supporting broad and phase specific therapeutic potential of multiple candidates in COVID-19","volume":"148","author":"Sharma","year":"2021","journal-title":"Cytokine"},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Cusato, J., Manca, A., Palermiti, A., Mula, J., Costanzo, M., Antonucci, M., Trunfio, M., Corcione, S., Chiara, F., and De Vivo, E.D. (2023). COVID-19: A Possible Contribution of the MAPK Pathway. Biomedicines, 11.","DOI":"10.3390\/biomedicines11051459"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1093\/nsr\/nwaa041","article-title":"Pathogenic T-cells and inflammatory monocytes incite inflammatory storms in severe COVID-19 patients","volume":"7","author":"Zhou","year":"2020","journal-title":"Natl. Sci. Rev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"2620","DOI":"10.1172\/JCI137244","article-title":"Clinical and immunological features of severe and moderate coronavirus disease 2019","volume":"130","author":"Chen","year":"2020","journal-title":"J. Clin. InvestIG."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2145","DOI":"10.3389\/fimmu.2020.02145","article-title":"Re-analysis of Single Cell Transcriptome Reveals That the NR3C1-CXCL8-Neutrophil Axis Determines the Severity of COVID-19","volume":"11","author":"Park","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1080\/22221751.2020.1747363","article-title":"Transcriptomic characteristics of bronchoalveolar lavage fluid and peripheral blood mononuclear cells in COVID-19 patients","volume":"9","author":"Xiong","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.3389\/fgene.2023.1105673","article-title":"A single-cell atlas reveals shared and distinct immune responses and metabolic profiles in SARS-CoV-2 and HIV-1 infections","volume":"14","author":"Pan","year":"2023","journal-title":"Front. Genet."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1126\/science.abc6027","article-title":"Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients","volume":"369","author":"Hadjadj","year":"2020","journal-title":"Science"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1043219","DOI":"10.3389\/fimmu.2022.1043219","article-title":"Blood transcriptome responses in patients correlate with severity of COVID-19 disease","volume":"13","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"694243","DOI":"10.3389\/fimmu.2021.694243","article-title":"High-Density Blood Transcriptomics Reveals Precision Immune Signatures of SARS-CoV-2 Infection in Hospitalized Individuals","volume":"12","author":"Prokop","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.cell.2020.10.037","article-title":"Multi-Omics Resolves a Sharp Disease-State Shift between Mild and Moderate COVID-19","volume":"183","author":"Su","year":"2020","journal-title":"Cell"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/s41591-021-01329-2","article-title":"Single-cell multi-omics analysis of the immune response in COVID-19","volume":"27","author":"Stephenson","year":"2021","journal-title":"Nat. Med."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.cels.2020.10.003","article-title":"Large-Scale Multi-omic Analysis of COVID-19 Severity","volume":"12","author":"Overmyer","year":"2021","journal-title":"Cell Syst."},{"key":"ref_122","doi-asserted-by":"crossref","unstructured":"Zarkovic, N., Jakovcevic, A., Mataic, A., Jaganjac, M., Vukovic, T., Waeg, G., and Zarkovic, K. (2022). Post-mortem Findings of Inflammatory Cells and the Association of 4-Hydroxynonenal with Systemic Vascular and Oxidative Stress in Lethal COVID-19. Cells, 11.","DOI":"10.3390\/cells11030444"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1410","DOI":"10.1016\/j.immuni.2023.05.007","article-title":"Resource Multi-omics blood atlas reveals unique features of immune and platelet responses to SARS-CoV-2 Omicron breakthrough infection","volume":"56","author":"Wang","year":"2023","journal-title":"Immunity"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Vlasova-St Louis, I., Musubire, A.K., Meya, D.B., Nabeta, H.W., Mohei, H., Boulware, D.R., and Bohjanen, P.R. (2021). Transcriptomic biomarker pathways associated with death in HIV-infected patients with cryptococcal meningitis. BMC Med. Genom., 14.","DOI":"10.1186\/s12920-021-00914-1"},{"key":"ref_125","first-page":"133","article-title":"Immune Restoration Disorders in Patients with AIDS and Tuberculosis: Novel Treatment Approaches","volume":"4","author":"Kellampalli","year":"2021","journal-title":"ACTA Sci. Microbiol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"ofy157","DOI":"10.1093\/ofid\/ofy157","article-title":"Transcriptomic predictors of paradoxical cryptococcosis-associated immune reconstitution inflammatory syndrome","volume":"5","author":"Louis","year":"2018","journal-title":"Open Forum Infect. Dis."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Mohei, H., Kellampalli, U., and Louis, I.V. (2019). Immune Reconstitution Disorders: Spotlight on Interferons. Int. J. Biomed. Investig., 2.","DOI":"10.31531\/2581-4745.1000119"},{"key":"ref_128","first-page":"33","article-title":"Post-transcriptional regulation of cytokine expression and signaling","volume":"19","author":"Guo","year":"2018","journal-title":"Curr. Trends Immunol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"695972","DOI":"10.3389\/fimmu.2021.695972","article-title":"Severe COVID-19 Is Characterized by an Impaired Type I Interferon Response and Elevated Levels of Arginase Producing Granulocytic Myeloid Derived Suppressor Cells","volume":"12","author":"Dean","year":"2021","journal-title":"Front. Immunol."},{"key":"ref_130","unstructured":"Goldstrohm, K. (2016). Post-Transcriptional Mechanisms in Endocrine Regulation, Springer."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"4219","DOI":"10.1021\/acs.jproteome.0c00326","article-title":"Proteomics and Informatics for Understanding Phases and Identifying Biomarkers in COVID-19 Disease","volume":"19","author":"Whetton","year":"2020","journal-title":"J. Proteome Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"1027122","DOI":"10.3389\/fimmu.2022.1027122","article-title":"Targeted proteomics identifies circulating biomarkers associated with active COVID-19 and post-COVID-19","volume":"13","author":"Zoodsma","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1016\/j.immuni.2020.10.008","article-title":"Plasma Proteomics Identify Biomarkers and Pathogenesis of COVID-19","volume":"53","author":"Shu","year":"2020","journal-title":"Immunity"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"4417","DOI":"10.1021\/acs.jproteome.0c00365","article-title":"Serum Proteomics in COVID-19 Patients: Altered Coagulation and Complement Status as a Function of IL-6 Level","volume":"19","author":"Thomas","year":"2020","journal-title":"J. Proteome Res."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"581338","DOI":"10.3389\/fimmu.2020.581338","article-title":"Pro- and Anti-Inflammatory Responses in Severe COVID-19-Induced Acute Respiratory Distress Syndrome\u2014An Observational Pilot Study","volume":"11","author":"Notz","year":"2020","journal-title":"Front. Immunol."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1002\/cyto.a.24516","article-title":"COVID-19: Using high-throughput flow cytometry to dissect clinical heterogeneity","volume":"103","author":"Hayday","year":"2023","journal-title":"Cytom. Part A"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Costanzo, M., Caterino, M., Fedele, R., Cevenini, A., Pontillo, M., Barra, L., and Ruoppolo, M. (2022). COVIDomics: The Proteomic and Metabolomic Signatures of COVID-19. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23052414"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s12931-023-02364-y","article-title":"Targeted plasma proteomics reveals signatures discriminating COVID-19 from sepsis with pneumonia","volume":"24","author":"Medina","year":"2023","journal-title":"Respir. Res."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1186\/s10020-023-00610-z","article-title":"Organ and cell-specific biomarkers of Long-COVID identified with targeted proteomics and machine learning","volume":"29","author":"Patel","year":"2023","journal-title":"Mol. Med."},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Bozorgmehr, N., Mashhouri, S., Rosero, E.P., Xu, L., Shahbaz, S., Sligl, W., Osman, M., Kutsogiannis, D.J., Macintyre, E., and O\u2019neil, C.R. (2021). Galectin-9, a player in cytokine release syndrome and a surrogate diagnostic biomarker in SARS-CoV-2 infection. MBio, 12.","DOI":"10.1128\/mBio.00384-21"},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Iwasaki-Hozumi, H., Maeda, Y., Niki, T., Chagan-Yasutan, H., Bai, G., Matsuba, T., Furushima, D., Ashino, Y., and Hattori, T. (2023). Plasma N-Cleaved Galectin-9 Is a Surrogate Marker for Determining the Severity of COVID-19 and Monitoring the Therapeutic Effects of Tocilizumab. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24043591"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41467-022-28639-4","article-title":"Prognostic tools and candidate drugs based on plasma proteomics of patients with severe COVID-19 complications","volume":"13","author":"Abdesselem","year":"2022","journal-title":"Nat. Commun."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Toro-Huamanchumo, C.J., Benites-Meza, J.K., Mamani-Garc\u00eda, C.S., Bustamante-Paytan, D., Gracia-Ramos, A.E., Diaz-V\u00e9lez, C., and Barboza, J.J. (2022). Efficacy of Colchicine in the Treatment of COVID-19 Patients: A Systematic Review and Meta-Analysis. J. Clin. Med., 11.","DOI":"10.3390\/jcm11092615"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"220099","DOI":"10.1183\/16000617.0099-2022","article-title":"Inhaled corticosteroids for the treatment of COVID-19","volume":"31","author":"Bafadhel","year":"2022","journal-title":"Eur. Respir. Rev."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"4543","DOI":"10.1038\/s41467-021-24482-1","article-title":"The trans-omics landscape of COVID-19","volume":"12","author":"Wu","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"16019","DOI":"10.1038\/s41598-022-20087-w","article-title":"Upregulation of interleukin-19 in saliva of patients with COVID-19","volume":"12","author":"Hafezi","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"465","DOI":"10.5483\/BMBRep.2022.55.9.077","article-title":"Establishment of the large-scale longitudinal multi-omics dataset in COVID-19 patients: Data profile and biospecimen","volume":"55","author":"Jo","year":"2022","journal-title":"BMB Rep."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"100663","DOI":"10.1016\/j.xcrm.2022.100663","article-title":"The IL-1\u03b2, IL-6, and TNF cytokine triad is associated with post-acute sequelae of COVID-19","volume":"3","author":"Willscher","year":"2022","journal-title":"Cell Rep. Med."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"4569","DOI":"10.1038\/s41467-021-24824-z","article-title":"Integrative genomic analyses identify susceptibility genes underlying COVID-19 hospitalization","volume":"12","author":"Pathak","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"20543581211056479","DOI":"10.1177\/20543581211056479","article-title":"The Impact of COVID-19 on Patients With ADPKD","volume":"8","author":"Kutky","year":"2021","journal-title":"Can. J. Kidney Health Dis."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"909714","DOI":"10.3389\/fgene.2022.909714","article-title":"Network Embedding Across Multiple Tissues and Data Modalities Elucidates the Context of Host Factors Important for COVID-19 Infection","volume":"13","author":"Hu","year":"2022","journal-title":"Front. Genet."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"D896","DOI":"10.1093\/nar\/gkac1019","article-title":"COMBATdb: A database for the COVID-19 Multi-Omics Blood ATlas","volume":"51","author":"Wang","year":"2023","journal-title":"Nucleic Acids Res."},{"key":"ref_153","first-page":"e13529","article-title":"Can Big Data and Machine Learning Improve Our Understanding of Acute Respiratory Distress Syndrome?","volume":"13","author":"Bhattarai","year":"2021","journal-title":"Cureus"},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Lipman, D., Safo, S.E., and Chekouo, T. (2022). Multi-omic analysis reveals enriched pathways associated with COVID-19 and COVID-19 severity. PLoS ONE, 17.","DOI":"10.1371\/journal.pone.0267047"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"100277","DOI":"10.1016\/j.mcpro.2022.100277","article-title":"Early Prediction of COVID-19 Patient Survival by Targeted Plasma Multi-Omics and Machine Learning","volume":"21","author":"Richard","year":"2022","journal-title":"Mol. Cell. Proteom."},{"key":"ref_156","doi-asserted-by":"crossref","unstructured":"Liu, X., Hasan, M.R., Ahmed, K.A., and Hossain, M.Z. (2023). Machine learning to analyse omic-data for COVID-19 diagnosis and prognosis. BMC Bioinform., 24.","DOI":"10.1186\/s12859-022-05127-6"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s13167-023-00317-5","article-title":"Multi-omics and immune cells\u2019 profiling of COVID-19 patients for ICU admission prediction: In silico analysis and an integrated machine learning-based approach in the framework of Predictive, Preventive, and Personalized Medicine","volume":"14","author":"Zhu","year":"2023","journal-title":"EPMA J."},{"key":"ref_158","doi-asserted-by":"crossref","unstructured":"de Andr\u00e9s-Galiana, E.J., Fern\u00e1ndez-Mart\u00ednez, J.L., \u00c1lvarez-Machancoses, \u00d3., Bea, G., Galmarini, C.M., and Kloczkowski, A. (2022). Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19. Comput. Biol. Med., 149.","DOI":"10.1016\/j.compbiomed.2022.106029"},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"704205","DOI":"10.3389\/fphar.2021.704205","article-title":"The Drug Repurposing for COVID-19 Clinical Trials Provide Very Effective Therapeutic Combinations: Lessons Learned From Major Clinical Studies","volume":"12","author":"Chakraborty","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Mousavi, S., Zare, S., Mirzaei, M., and Feizi, A. (2022). Novel Drug Design for Treatment of COVID-19: A Systematic Review of Preclinical Studies. Can. J. Infect. Dis. Med. Microbiol., 2022.","DOI":"10.1155\/2022\/2044282"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1001\/jama.2020.16866","article-title":"COVID-19 and mRNA vaccines\u2014First large test for a new approach","volume":"324","author":"Abbasi","year":"2020","journal-title":"JAMA\u2014J. Am. Med. Assoc."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Akinosoglou, K., Rigopoulos, E.A., Schinas, G., Kaiafa, G., Polyzou, E., Tsoupra, S., Tzouvelekis, A., Gogos, C., and Savopoulos, C. (2023). Remdesivir Use in the Real-World Setting: An Overview of Available Evidence. Viruses, 15.","DOI":"10.3390\/v15051167"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"e151","DOI":"10.15190\/d.2022.10","article-title":"Remdesivir: The first FDA-approved anti-COVID-19 Treatment for Young Children","volume":"10","author":"Chera","year":"2022","journal-title":"Discoveries"},{"key":"ref_164","first-page":"P1","article-title":"SARS-CoV-2 infection, hypercoagulability and hereditary thrombophilia factors","volume":"33","author":"Kiraz","year":"2022","journal-title":"Gazi Med. J."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1056\/NEJMoa2116044","article-title":"Molnupiravir for Oral Treatment of Covid-19 in Nonhospitalized Patients","volume":"386","author":"Musungaie","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"e222968","DOI":"10.1001\/jamahealthforum.2022.2968","article-title":"FDA Authorizes Pharmacists to Prescribe Oral Antiviral Medication for COVID-19","volume":"3","author":"Stephenson","year":"2022","journal-title":"JAMA Health Forum"},{"key":"ref_167","doi-asserted-by":"crossref","unstructured":"Chourasia, P., Maringanti, B.S., Edwards-Fligner, M., Gangu, K., Bobba, A., Sheikh, A.B., and Shekhar, R. (2023). Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines\u2014A Scoping Review. Vaccines, 11.","DOI":"10.3390\/vaccines11010107"},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"1129459","DOI":"10.3389\/fimmu.2023.1129459","article-title":"Therapeutic trials for long COVID-19: A call to action from the interventions taskforce of the RECOVER initiative","volume":"14","author":"Bonilla","year":"2023","journal-title":"Front. Immunol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"1941","DOI":"10.1016\/S0140-6736(22)00519-0","article-title":"Remdesivir and three other drugs for hospitalised patients with COVID-19: Final results of the WHO Solidarity randomised trial and updated meta-analyses","volume":"399","author":"Pan","year":"2022","journal-title":"Lancet"},{"key":"ref_170","unstructured":"Louis, I.V., and Abadie, J. (2022). RNA Therapeutics\u2014History, Design, Manufacturing, and Applications, IntechOpen."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/infdis\/jiac206","article-title":"Real-World Evidence of the Neutralizing Monoclonal Antibody Sotrovimab for Preventing Hospitalization and Mortality in COVID-19 Outpatients","volume":"226","author":"Aggarwal","year":"2022","journal-title":"J. Infect. Dis."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1001\/jama.2021.0202","article-title":"Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: A randomized clinical trial","volume":"325","author":"Gottlieb","year":"2021","journal-title":"JAMA\u2014J. Am. Med. Assoc."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1038\/s41467-023-38435-3","article-title":"Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants","volume":"14","author":"Tamura","year":"2023","journal-title":"Nat. Commun."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1056\/NEJMoa2209760","article-title":"Early Treatment with Pegylated Interferon Lambda for Covid-19","volume":"388","author":"Reis","year":"2023","journal-title":"N. Engl. J. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"m2980","DOI":"10.1136\/bmj.m2980","article-title":"Drug treatments for covid-19: Living systematic review and network meta-Analysis","volume":"370","author":"Siemieniuk","year":"2020","journal-title":"BMJ"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1016\/S2213-2600(21)00331-3","article-title":"Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial","volume":"9","author":"Marconi","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"109906","DOI":"10.1016\/j.mehy.2020.109906","article-title":"Novel therapeutic targets for SARS-CoV-2-induced acute lung injury: Targeting a potential IL-1\u03b2\/neutrophil extracellular traps feedback loop","volume":"143","author":"Yaqinuddin","year":"2020","journal-title":"Med. Hypotheses"},{"key":"ref_178","unstructured":"(2023, June 04). NCT04482699. RAPA-501-Allo Off-the-Shelf Therapy of COVID-19. Clinicaltrials 2020, Available online: https:\/\/clinicaltrials.gov\/show\/NCT04482699."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1097\/CCM.0000000000005756","article-title":"Outcomes and Adverse Effects of Baricitinib Versus Tocilizumab in the Management of Severe COVID-19","volume":"51","author":"Peterson","year":"2023","journal-title":"Crit. Care Med."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.jpeds.2020.06.045","article-title":"Multisystem Inflammatory Syndrome in Children Associated with Severe Acute Respiratory Syndrome Coronavirus 2 Infection (MIS-C): A Multi-institutional Study from New York City","volume":"224","author":"Kaushik","year":"2020","journal-title":"J. Pediatr."},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"8059","DOI":"10.1038\/s41598-021-86859-y","article-title":"Role of interferon therapy in severe COVID-19: The COVIFERON randomized controlled trial","volume":"11","author":"Shokouhi","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s40001-021-00591-x","article-title":"Clinical characteristics and outcomes of critically ill mechanically ventilated COVID-19 patients receiving interleukin-6 receptor antagonists and corticosteroid therapy: A preliminary report from a multinational registry","volume":"26","author":"Amer","year":"2021","journal-title":"Eur. J. Med. Res."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial","volume":"397","author":"Abani","year":"2021","journal-title":"Lancet"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"107102","DOI":"10.1016\/j.intimp.2020.107102","article-title":"Subcutaneous tocilizumab in adults with severe and critical COVID-19: A prospective open-label uncontrolled multicenter trial","volume":"89","author":"Malekzadeh","year":"2020","journal-title":"Int. Immunopharmacol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"A655","DOI":"10.1016\/j.chest.2022.08.512","article-title":"The added clinical value of tocilizymab in treating adults hospitalized with COVID-19: A retrospective cohort study","volume":"162","author":"Ata","year":"2022","journal-title":"Chest"},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/S2213-2600(21)00099-0","article-title":"Sarilumab in patients admitted to hospital with severe or critical COVID-19: A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"9","author":"Lescure","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"2710","DOI":"10.1038\/s41375-021-01299-x","article-title":"Siltuximab downregulates interleukin-8 and pentraxin 3 to improve ventilatory status and survival in severe COVID-19","volume":"35","author":"Gritti","year":"2021","journal-title":"Leukemia"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"00605","DOI":"10.1183\/23120541.00605-2022","article-title":"Nebulised interferon-\u03b21a (SNG001) in hospitalised COVID-19: SPRINTER phase III study","volume":"9","author":"Monk","year":"2023","journal-title":"ERJ Open Res."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.chom.2020.07.005","article-title":"Retrospective Multicenter Cohort Study Shows Early Interferon Therapy Is Associated with Favorable Clinical Responses in COVID-19 Patients","volume":"28","author":"Wang","year":"2020","journal-title":"Cell Host Microbe"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.arcmed.2022.03.002","article-title":"Tranilast as an Adjunctive Therapy in Hospitalized Patients with Severe COVID-19: A Randomized Controlled Trial","volume":"53","author":"Nashibi","year":"2022","journal-title":"Arch. Med. Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.ijid.2020.12.073","article-title":"Canakinumab as treatment for COVID-19-related pneumonia: A prospective case-control study","volume":"104","author":"Generali","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"e325","DOI":"10.1016\/S2665-9913(20)30127-2","article-title":"Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study","volume":"2","author":"Cavalli","year":"2020","journal-title":"Lancet Rheumatol."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"e66125","DOI":"10.7554\/eLife.66125","article-title":"An open label trial of anakinra to prevent respiratory failure in COVID-19","volume":"10","author":"Kyriazopoulou","year":"2021","journal-title":"Elife"},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1016\/S0140-6736(22)01109-6","article-title":"Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial and updated meta-analysis","volume":"400","author":"Abani","year":"2022","journal-title":"Lancet"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1056\/NEJMoa2031994","article-title":"Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19","volume":"384","author":"Kalil","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_196","unstructured":"(2023, June 06). NCT04970719. Baricitinib in Hospitalized Covid-19 Patients With Diabetes Mellitus, Available online: https:\/\/clinicaltrials.gov\/show\/NCT04970719."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1056\/NEJMoa2101643","article-title":"Tofacitinib in Patients Hospitalized with Covid-19 Pneumonia","volume":"385","author":"Quirk","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/annrheumdis-2020-217871","article-title":"Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: Data from the COVID-19 Global Rheumatology Alliance physician-reported registry","volume":"79","author":"Gianfrancesco","year":"2020","journal-title":"Ann. Rheum. Dis."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"e2129639","DOI":"10.1001\/jamanetworkopen.2021.29639","article-title":"Association between Tumor Necrosis Factor Inhibitors and the Risk of Hospitalization or Death among Patients with Immune-Mediated Inflammatory Disease and COVID-19","volume":"4","author":"Izadi","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S2213-2600(21)00460-4","article-title":"Namilumab or infliximab compared with standard of care in hospitalised patients with COVID-19 (CATALYST): A randomised, multicentre, multi-arm, multistage, open-label, adaptive, phase 2, proof-of-concept trial","volume":"10","author":"Fisher","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S2213-2600(21)00494-X","article-title":"Lenzilumab in hospitalised patients with COVID-19 pneumonia (LIVE-AIR): A phase 3, randomised, placebo-controlled trial","volume":"10","author":"Temesgen","year":"2022","journal-title":"Lancet Respir. Med."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.ijid.2021.05.055","article-title":"Efficacy and safety of nintedanib for pulmonary fibrosis in severe pneumonia induced by COVID-19: An interventional study","volume":"108","author":"Umemura","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/14712598.2021.1905794","article-title":"A two-arm, randomized, controlled, multi-centric, open-label phase-2 study to evaluate the efficacy and safety of Itolizumab in moderate to severe ARDS patients due to COVID-19","volume":"21","author":"Kumar","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1684\/ecn.2021.0463","article-title":"Interleukin 17 antagonist netakimab is effective and safe in the new coronavirus infection (COVID-19)","volume":"32","author":"Maslennikov","year":"2021","journal-title":"Eur. Cytokine Netw."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1016\/S2213-2600(21)00377-5","article-title":"Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): A factorial, randomised, controlled trial","volume":"9","author":"Declercq","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"583","DOI":"10.2217\/pme-2021-0077","article-title":"Personalized therapy: Can it tame the COVID-19 monster?","volume":"18","author":"Arish","year":"2021","journal-title":"Per. Med."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"23652","DOI":"10.1073\/pnas.2008281117","article-title":"A SARS-CoV-2 vaccine candidate would likely match all currently circulating variants","volume":"117","author":"Dearlove","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/j.ijid.2021.03.050","article-title":"Interim estimates in null models of COVID-19 vaccine effectiveness","volume":"106","author":"Lisewski","year":"2021","journal-title":"Int. J. Infect. Dis."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: An observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1473-3099(20)30783-0","article-title":"What reinfections mean for COVID-19","volume":"21","author":"Iwasaki","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/S1473-3099(20)30764-7","article-title":"Genomic evidence for reinfection with SARS-CoV-2: A case study","volume":"21","author":"Tillett","year":"2021","journal-title":"Lancet Infect. Dis."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/infdis\/jiad074","article-title":"Population-Based Severe Acute Respiratory Syndrome Coronavirus 2 Whole-Genome Sequencing and Contact Tracing During the Coronavirus Disease 2019 Pandemic in Switzerland","volume":"228","author":"Anderegg","year":"2023","journal-title":"J. Infect. Dis."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"e2946","DOI":"10.1093\/cid\/ciaa1275","article-title":"Coronavirus Disease 2019 (COVID-19) Re-infection by a Phylogenetically Distinct Severe Acute Respiratory Syndrome Coronavirus 2 Strain Confirmed by Whole Genome Sequencing","volume":"73","author":"To","year":"2021","journal-title":"Clin. Infect. Dis."},{"key":"ref_214","doi-asserted-by":"crossref","unstructured":"Satpati, P., Sarangi, S., Gantait, K., Endow, S., Mandal, N., Panchanan, K., Subhadip, B., and Soham, S. (2020). Sero-surveillance (IgG) of SARS-CoV-2 among Asymptomatic General population of Paschim Medinipur, West Bengal, India. medRxiv.","DOI":"10.1101\/2020.09.12.20193219"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.4103\/jfmpc.jfmpc_1079_20","article-title":"\u201cCOVID Vaccine\u201d is not the excuse to delay adaptation to the \u201cNew-Normal\u201d","volume":"9","author":"Deshmukh","year":"2020","journal-title":"J. Fam. Med. Prim. Care"},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2217\/fvl-2021-0243","article-title":"Identifying asymptomatic cases during the mass COVID-19 vaccination campaign: Insights and implications for policy makers","volume":"17","author":"Chirico","year":"2022","journal-title":"Future Virol."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1590\/1516-3180.2020.0618.r1.10122020","article-title":"Impact of super-spreaders on COVID-19: Systematic review","volume":"139","author":"Rambo","year":"2021","journal-title":"Sao Paulo Med. J."},{"key":"ref_218","unstructured":"WHO (2023, June 17). Tracking SARS-CoV-2 Variants. Available online: https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\/."},{"key":"ref_219","unstructured":"ClinicalTrials (2023, May 30). A Study of SARS CoV-2 Infection and Potential Transmission in Individuals Immunized with Moderna COVID-19 Vaccine (CoVPN 3006). NCT04811664, Available online: https:\/\/www.clinicaltrials.gov\/ct2\/show\/study\/NCT04811664."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: Modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1774","DOI":"10.1056\/NEJMc2101927","article-title":"SARS-CoV-2 Infection after Vaccination in Health Care Workers in California","volume":"384","author":"Keehner","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1021\/acsinfecdis.1c00557","article-title":"Emerging Vaccine-Breakthrough SARS-CoV-2 Variants","volume":"8","author":"Wang","year":"2022","journal-title":"ACS Infect. Dis."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(21)00460-6","article-title":"Risk factors and disease profile of post-vaccination SARS-CoV-2 infection in UK users of the COVID Symptom Study app: A prospective, community-based, nested, case-control study","volume":"22","author":"Antonelli","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1016\/j.vaccine.2023.02.008","article-title":"Protective effect of COVID-19 vaccination against long COVID syndrome: A systematic review and meta-analysis","volume":"41","author":"Watanabe","year":"2023","journal-title":"Vaccine"},{"key":"ref_225","unstructured":"Marks, P. (2023, June 29). Coronavirus (COVID-19) Update: FDA Recommends Inclusion of Omicron BA.4\/5 Component for COVID-19 Vaccine Booster Doses, Available online: https:\/\/www.fda.gov\/news-events\/press-announcements\/coronavirus-covid-19-update-fda-recommends-inclusion-omicron-ba45-component-covid-19-vaccine-booster."},{"key":"ref_226","unstructured":"Pfizer & BioNTech (2023, May 29). Pfizer and BioNTech Submit Application to U.S. FDA for Emergency Use Authorization of Omicron BA.4\/BA.5-Adapted Bivalent COVID-19 Vaccine. Available online: https:\/\/www.pfizer.com\/news\/press-release\/press-release-detail\/pfizer-and-biontech-submit-application-us-fda-emergency-use."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jare.2021.10.012","article-title":"The role of mild and asymptomatic infections on COVID-19 vaccines performance: A modeling study","volume":"39","author":"Aguiar","year":"2022","journal-title":"J. Adv. Res."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1002\/ski2.139","article-title":"Ixekizumab successfully treated severe pityriasis rubra pilaris after COVID-19 vaccination","volume":"3","author":"Liu","year":"2023","journal-title":"Ski. Health Dis."}],"container-title":["Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2571-841X\/6\/4\/45\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:55:36Z","timestamp":1760129736000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2571-841X\/6\/4\/45"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,22]]},"references-count":228,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["reports6040045"],"URL":"https:\/\/doi.org\/10.3390\/reports6040045","relation":{},"ISSN":["2571-841X"],"issn-type":[{"value":"2571-841X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,22]]}}}